trial · primary record
Tolvaptan Suspension
Autosomal Recessive Polycystic Kidney (ARPKD)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2028-12-28 |
| Primary endpoint | Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) |
| Registry ID | NCT04782258 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:15.840Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04782258
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.